Fol News

Tutti gli approfondimenti
Tutte le notizie

Chfs ex ssh- Nasdaq-... così non si fa confusione!

CHF Solutions Announces Launch of Aquapheresis Therapy Using Aquadex FlexFlow® System at the Baylor Scott & White Health System in Texas
GlobeNewswire GlobeNewswire•January 22, 2020
EDEN PRAIRIE, Minn., Jan. 22, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (CHFS) today announced that Texas-based health system, Baylor Scott & White Health has initiated offering aquapheresis therapy using the company’s Aquadex FlexFlow® system at its Baylor Scott & White Medical Center in Temple, Texas.

“Fluid overload continues to be an issue to be managed in the acute and chronic care settings, and CHF Solutions’ Aquadex FlexFlow System has continually proven to be a viable and easy-to-maintain solution for managing these patients and improving their quality of life while reducing the cost of care,” said John Erb, CEO of CHF Solutions. “We are proud to provide products to Baylor Scott & White Medical Center -Temple and look forward to assisting its clinicians in the care of their fluid overloaded patients.”

Baylor Scott & White Health is the largest not-for-profit health care system in Texas and one of the largest in the United States. With a commitment to and a track record of innovation, collaboration, integrity and compassion for the patient, Baylor Scott & White Health stands to be one of the nation’s exemplary health care organizations. Its mission is to serve all people by providing personalized health and wellness through exemplary care, education and research as a Christian ministry of healing
 
laniero ha scritto:
CHF Solutions Announces Launch of Aquapheresis Therapy Using Aquadex FlexFlow® System at the Baylor Scott & White Health System in Texas
GlobeNewswire GlobeNewswire•January 22, 2020
EDEN PRAIRIE, Minn., Jan. 22, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (CHFS) today announced that Texas-based health system, Baylor Scott & White Health has initiated offering aquapheresis therapy using the company’s Aquadex FlexFlow® system at its Baylor Scott & White Medical Center in Temple, Texas.

“Fluid overload continues to be an issue to be managed in the acute and chronic care settings, and CHF Solutions’ Aquadex FlexFlow System has continually proven to be a viable and easy-to-maintain solution for managing these patients and improving their quality of life while reducing the cost of care,” said John Erb, CEO of CHF Solutions. “We are proud to provide products to Baylor Scott & White Medical Center -Temple and look forward to assisting its clinicians in the care of their fluid overloaded patients.”

Baylor Scott & White Health is the largest not-for-profit health care system in Texas and one of the largest in the United States. With a commitment to and a track record of innovation, collaboration, integrity and compassion for the patient, Baylor Scott & White Health stands to be one of the nation’s exemplary health care organizations. Its mission is to serve all people by providing personalized health and wellness through exemplary care, education and research as a Christian ministry of healing
Clicca per espandere...

Come mai reagisce così male alla news?
 
Appena vista. Da +20 a -20 ma che è successo?!
 
...io ieri ho realizzato a 1,13 dopo l’apertura perché vedevo molti volumi e il titolo che non decollava seriamente per cui non ci ho pensato due volte, è vero anche che ormai con i titoli segnalati da mastro siamo abituati a rialzi monstre ma a volte meglio accontentarsi ;)
 
mastrodaniel dacci la tua opinione sul titolo, cosa e meglio fare per te?
 
Sempre più giù, solo si capisse il motivo...
 
...quando un titolo scende senza motivo di solito è perché stanno diluendo ma è solo una mia ipotesi un quanto non conosco se chfs ha convertibili warrant tipo c ecc
 
out con un bel loss. con questi volumi ci azzerano
 
offering. Be si sapeva da più di un mese che l avrebbero fatta ci sono stati vari filling Che pronunciavano .....pensavo che la FDA dava via libera prima ...io sono uscito una settimana fa con un 30 % di gain ..bisogna accontentarsi
 
L'offerta è per 0,55$ ad azione il 28 gennaio, ma ora il titolo è a 0,48$. Non vale la pena acquistare in questo momento?
 
Devi accedere o registrarti per poter rispondere.
Indietro